Literature DB >> 24140348

Glypican-3 antibodies: a new therapeutic target for liver cancer.

Mingqian Feng1, Mitchell Ho2.   

Abstract

Glypican-3 (GPC3) is an emerging therapeutic target in hepatocellular carcinoma (HCC), even though the biological function of GPC3 remains elusive. Currently human (MDX-1414 and HN3) and humanized mouse (GC33 and YP7) antibodies that target GPC3 for HCC treatment are under different stages of preclinical or clinical development. Humanized mouse antibody GC33 is being evaluated in a phase II clinical trial. Human antibodies MDX-1414 and HN3 are under different stages of preclinical evaluation. Here, we summarize current evidence for GPC3 as a new target in liver cancer, discuss both its oncogenic function and its mode of actions for current antibodies, and evaluate potential challenges for GPC3-targeted anti-cancer therapies. Published by Elsevier B.V.

Entities:  

Keywords:  GC33; Glypican-3 (GPC3); HN3; Heparan sulfate proteoglycan; Hepatocellular carcinoma; YP7

Mesh：

Substances：

Year:  2013        PMID： 24140348      PMCID： PMC3947105          DOI： 10.1016/j.febslet.2013.10.002

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  57 in total

1.  Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.

Authors:  Xiao Ying Wang; Françoise Degos; Sylvie Dubois; Sandrine Tessiore; Mark Allegretta; Ronald D Guttmann; Serge Jothy; Jacques Belghiti; Pierre Bedossa; Valérie Paradis
Journal:  Hum Pathol       Date:  2006-08-10       Impact factor: 3.466

2.  Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.

Authors:  Louis Libbrecht; Tamara Severi; David Cassiman; Sara Vander Borght; Jacques Pirenne; Frederik Nevens; Chris Verslype; Jos van Pelt; Tania Roskams
Journal:  Am J Surg Pathol       Date:  2006-11       Impact factor: 6.394

3.  The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.

Authors:  Naoko Yamauchi; Akira Watanabe; Michiyo Hishinuma; Ken-Ichi Ohashi; Yutaka Midorikawa; Yasuyuki Morishita; Toshiro Niki; Junji Shibahara; Masaya Mori; Masatoshi Makuuchi; Yoshitaka Hippo; Tatsuhiko Kodama; Hiroko Iwanari; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Mod Pathol       Date:  2005-12       Impact factor: 7.842

4.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.

Authors:  Luca Di Tommaso; Giada Franchi; Young Nyun Park; Barbara Fiamengo; Annarita Destro; Emanuela Morenghi; Marco Montorsi; Guido Torzilli; Maurizio Tommasini; Luigi Terracciano; Luigi Tornillo; Raffaella Vecchione; Massimo Roncalli
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

5.  Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.

Authors:  Mariana I Capurro; Yun-Yan Xiang; Corrinne Lobe; Jorge Filmus
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

6.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

Authors:  Josep M Llovet; Yingbei Chen; Elisa Wurmbach; Sasan Roayaie; M Isabel Fiel; Myron Schwartz; Swan N Thung; Gregory Khitrov; Weijia Zhang; Augusto Villanueva; Carlo Battiston; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Scott L Friedman
Journal:  Gastroenterology       Date:  2006-09-19       Impact factor: 22.682

Review 7.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

8.  Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition.

Authors:  Kylie A Henderson; Victor A Streltsov; Andrew M Coley; Olan Dolezal; Peter J Hudson; Adrian H Batchelor; Aditi Gupta; Tao Bai; Vincent J Murphy; Robin F Anders; Michael Foley; Stewart D Nuttall
Journal:  Structure       Date:  2007-11       Impact factor: 5.006

9.  Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.

Authors:  Caroline D M Witjes; Fiebo J W ten Kate; Cornelis Verhoef; Robert A de Man; Jan N M IJzermans
Journal:  J Clin Pathol       Date:  2013-04-12       Impact factor: 3.411

10.  Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases.

Authors:  Debra L Zynger; Anita Gupta; Chunyan Luan; Pauline M Chou; Guang-Yu Yang; Ximing J Yang
Journal:  Hum Pathol       Date:  2007-10-18       Impact factor: 3.466
View more
  39 in total

Review 1.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Immunological landscape and immunotherapy of hepatocellular carcinoma.

Authors:  Jesús Prieto; Ignacio Melero; Bruno Sangro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

Review 3.  Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection.

Authors:  Bingnan Zhang; Richard S Finn
Journal:  Liver Cancer       Date:  2016-05-10       Impact factor: 11.740

4.  Aptamers against Cells Overexpressing Glypican 3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution.

Authors:  Liqin Zhang; Zunyi Yang; Thu Le Trinh; I-Ting Teng; Sai Wang; Kevin M Bradley; Shuichi Hoshika; Qunfeng Wu; Sena Cansiz; Diane J Rowold; Christopher McLendon; Myong-Sang Kim; Yuan Wu; Cheng Cui; Yuan Liu; Weijia Hou; Kimberly Stewart; Shuo Wan; Chen Liu; Steven A Benner; Weihong Tan
Journal:  Angew Chem Int Ed Engl       Date:  2016-09-07       Impact factor: 15.336

5.  Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.

Authors:  Hirofumi Hanaoka; Takahito Nakajima; Kazuhide Sato; Rira Watanabe; Yen Phung; Wei Gao; Toshiko Harada; Insook Kim; Chang H Paik; Peter L Choyke; Mitchell Ho; Hisataka Kobayashi
Journal:  Nanomedicine (Lond)       Date:  2015       Impact factor: 5.307

6.  Heparan sulfate proteoglycans as targets for cancer therapy: a review.

Authors:  Jessica Oyie Sousa Onyeisi; Bianca Zaia Franco Ferreira; Helena Bonciani Nader; Carla Cristina Lopes
Journal:  Cancer Biol Ther       Date:  2020-11-12       Impact factor: 4.742

Review 7.  Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.

Authors:  Yukai He; Yuan Hong; Gerald J Mizejewski
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

8.  Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression.

Authors:  Shukun Han; Bing Han; Zhongmin Li; Du Sun
Journal:  Cell Cycle       Date:  2019-08-15       Impact factor: 4.534

Review 9.  Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Authors:  Tim F Greten; Chunwei Walter Lai; Guangfu Li; Kevin F Staveley-O'Carroll
Journal:  Gastroenterology       Date:  2018-10-01       Impact factor: 22.682

Review 10.  Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.

Authors:  Leidy D Caraballo Galva; Lun Cai; Yanxia Shao; Yukai He
Journal:  J Genet Genomics       Date:  2020-01-28       Impact factor: 4.275
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.